Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003641 · ClinicalTrials.gov registry record · Phase 3
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
A Phase 3 study of Melanoma (Skin), sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
- 20
- Study locations
NCT00003641: Active Phase 3 study of Melanoma (Skin), sponsored by ECOG-ACRIN Cancer Research Group.
NCT00003641 is a Phase 3 study of Melanoma (Skin) that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1,150 participants, above the 99-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (1062% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003641, a Phase 3 study of Melanoma (Skin), is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
Primary Outcome
Relapse-free survival (RFS) was defined as time from randomization to disease relapse or death from any cause, whichever occurred first. Patients without disease relapse were censored at last disease assessment date known of free of relapse. Kaplan-Meier method was used to estimate 5-year RFS rate in the intent-to-treat (ITT) patients.
Conditions Studied
Interventions
- BIOLOGICAL interferon alfa-2b
- OTHER observation
Study Locations (20)
California
- Kaiser Permanente - Deer Valley - Antioch
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- Peninsula Medical Center - Burlingame
- Southern California Permanente Medical Group - Downey
- Kaiser Permanente - Fremont - Fremont
- Marin Cancer Institute at Marin General Hospital - Greenbrae
- Kaiser Permanente Medical Center - Hayward - Hayward
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
- Kaiser Permanente Medical Center - Oakland - Oakland
- Veterans Affairs Medical Center - Palo Alto - Palo Alto
- Kaiser Permanente Medical Center - Redwood City - Redwood City
- Kaiser Permanente Medical Center - Richmond - Richmond
- Kaiser Permanente Medical Center - Roseville - Roseville
- Sutter Cancer Center at Roseville Medical Center - Roseville
- Sutter Cancer Center - Sacramento
Alabama
- UAB Comprehensive Cancer Center - Birmingham
- University of South Alabama Mitchell Cancer Institute - Mobile
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Arizona
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 1999-03-25 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What the registry record for NCT00003641 still lists
NCT00003641 is an interventional study that assigns participants to a tested intervention. Its 1,150 participants enrollment target places it among the larger protocols in the corpus, above the 99-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (1062% higher).
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which interferon alfa-2b is the first listed.
NCT00003641 names 20 study sites across 4 states, led by California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00003641 about?
NCT00003641 is a clinical study titled "High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma". RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is s...
What is the current status of trial NCT00003641?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 1999-03-25. Estimated completion is 2026-12.
What conditions does trial NCT00003641 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00003641?
The interventions under investigation include: interferon alfa-2b (BIOLOGICAL), observation (OTHER).
Who is sponsoring clinical trial NCT00003641?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003641 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003641's enrollment target sits among peer trials
1,150 1st of 30 higher than 30 of 30 other Melanoma (Skin) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma (Skin) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
RECRUITING · NA
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
RECRUITING
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- NCT07293559 · 1,150 participants
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
- NCT07339423 · 1,150 participants · Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI